National Institute for Health Research announces the potential of new eyedrops as a novel approach to Ocular Neovascular Disorders. Until recently angiogenesis has been a complex process that is known to be vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. Ocular Neovascular Disorders with new eyedrops that inhibit Aganirsen (GS-101). In recent times therapies aimed at preventing angiogenic-mediated disorders must differentiate between healthy and pathological angiogenesis or neovascularisation for health and safety reasons. However it has been discovered now know that aganirsen is an antisense oligonucleotide that inhibits the insulin receptor substrate angiogenic pathway by targeting the IRS-1 messenger RNA. To date, studies of aganirsen have focused mainly on ocular disorders because of the ability to assess non-invasively the effect of the drug on neovascularisation and to address the unmet need for effective therapies in these blinding disorders. Aganirsen eye drops inhibit progressive corneal neovascularisation and appear to be well tolerated...This is because it has a different and potentially complementary mechanism of action and can be administered topically. Antisense oligonucleotides targeting IRS-1 may present a valuable new approach to control pathological angiogenesis in the eye and elsewhere.
Ocular neovascular disorders are a major cause of sight impairment worldwide. Aganirsen is a topical antisense oligonucleotide that inhibits IRS-1 and thus neovascularisation, without interfering with normal angiogenesis. Topical aganirsen significantly inhibits progressive corneal vascularisation and appears well tolerated. Authors 1 James W Bainbridge, 2 Vanya Loroch, £ Eric Viaud and 4 Claus Cursiefen 1. Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London (UCL), London, UK; 2. CEO, Loroch Communications, Essertines-sur-Rolle, Switzerland and Swiss Biotech Association, Zürich, Switzerland; 3...James W Bainbridge">here.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9974113.htm